In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. DENTSPLY SIRONA Inc. is one of them. DENTSPLY SIRONA Inc. (NASDAQ:XRAY), the world’s largest manufacturer of professional dental products and technologies, operates across imaging, CAD/CAM, endodontics, restoratives, and healthcare consumables through Wellspect. Its product portfolio includes intraoral scanners, 3D printers, motorized handpieces, and cloud-based platforms like DS Core, which support digital dentistry w ...

Key Takeaways XRAY's review concluded that retaining Wellspect offers more value than a sale.XRAY concludes that Wellspect leads in continence care with steady growth and strong cash flows.Wellspect's $2B market and pipeline back XRAY's long-term profitability strategy.Dentsply Sirona (XRAY) recently concluded that retaining the Wellspect business portfolio is likely to create more value for its stockholders compared to other strategic alternatives. CEO Dan Scavilla emphasized that, after a comprehensive st ...

PresentationJeffrey JohnsonSenior Research Analyst All right. Good afternoon. Why don't we get started? My name is Jeff Johnson. I'm the senior medical technology analyst at Baird. Our next presentation this afternoon is from Dentsply Sirona, a leading manufacturer of dental consumables and equipment across the globe. With us today from Dentsply, we're happy to have CFO, Matt Garth. Matt, I think you said we can just go straight into Q&A. ...

DENTSPLY SIRONA (NasdaqGS:XRAY) 2025 Conference September 09, 2025 01:25 PM ET Company ParticipantsMatthew Garth - EVP & CFOConference Call ParticipantsJeffrey Johnson - Senior Research AnalystJeffrey JohnsonLet's get to go. All right. We'll go. We won't talk Big Ten anymore. Exactly. All right. Good afternoon. Why don't we get started? My name is Jeff Johnson. I'm the Senior Medical Technology Analyst at Baird. Our next presentation this afternoon is from Dentsply Sirona, a leading manufacturer of dental c ...

PresentationErin Wilson WrightEquity Analyst Good afternoon, everyone. My name is Erin Wright, the health care services analyst at Morgan Stanley. We're happy to have with us Dentsply Sirona and the management team. We have CEO, Dan Scavilla, if I said that right, and Matt Garth, the CFO. Newly appointed management team is here. So we're really excited to have you here and give your views on the strategy and everything kind of going forward. But for more important disclosures, please see the Morgan Stanley ...

DENTSPLY SIRONA (NasdaqGS:XRAY) FY Conference September 08, 2025 02:35 PM ET Company ParticipantsMatthew Garth - EVP & CFODaniel Scavilla - President, CEO & DirectorConference Call ParticipantsErin Wright - Senior Equity Research Analyst - HealthcareErin WrightGood afternoon, everyone. My name is Erin Wright, the Healthcare Services Analyst at Morgan Stanley. We're happy to have with us Dentsply Sirona, the management team. We have CEO Dan Scavilla, and Matt Garza, the CFO. Newly appointed management team h ...

Determined that Wellspect will Deliver Greater Financial and Strategic Benefits to Stockholders as Part of the CompanyCHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company has completed the evaluation of strategic alternatives for its Wellspect Healthcare business (“Wellspect”), which was announced in February 2025. As a part of its review process, Dentsply Sirona considered a range of potential opportuni ...

期权市场动态 - 2026年1月16日到期、行权价2.5美元的看涨期权隐含波动率创下当日所有股票期权中的最高水平 [1] - 高隐含波动率表明市场预期DENTSPLY股价将出现大幅波动 可能由重大事件引发 [2] 公司基本面分析 - 公司当前Zacks评级为3（持有） 所属医疗牙科供应行业在Zacks行业排名中处于后24% [3] - 过去60天内 2名分析师上调当季每股收益预期至47美分 5名下调至46美分 共识预期下降1美分 [3] 期权交易策略 - 高隐含波动率可能催生交易机会 经验丰富的交易者常通过卖出期权溢价策略利用时间价值衰减获利 [4] - 交易者期望标的股票实际波动幅度低于市场预期 [4] 行业表现 - 医疗牙科供应行业整体表现疲弱 行业排名处于末段 [3]

公司业务概况 - 丹纳赫西诺拉公司专注于牙科和医疗保健解决方案的医疗技术领域 [1] - 公司核心业务包括消耗品(EDS)和Wellspect医疗保健两大主要收入板块 [1] - 这两大业务板块为公司提供了稳定的收入来源 [1] 公司基本信息 - 公司股票在纳斯达克交易所上市 交易代码为XRAY [1]

公司国际业务表现 - 公司2025年第二季度总收入为9.36亿美元，同比下降4.9% [4] - 欧洲市场收入占比43.2%（4.04亿美元），超出华尔街预期3.62%，环比增长11.6%，同比增长4.4% [5] - 其他地区收入占比25.5%（2.39亿美元），超出华尔街预期7.37%，环比增长11.2%，同比增长0.8% [6] 国际市场收入预测 - 华尔街预计当前财季总收入为9.0549亿美元（同比下降4.8%），其中欧洲和其他地区占比分别为39.1%（3.5386亿美元）和23.8%（2.1507亿美元） [7] - 全年收入预期为36.5亿美元（同比下降3.8%），欧洲和其他地区预计贡献41.4%（15.1亿美元）和24.2%（8.8444亿美元） [8] 股票表现 - 过去一个月股价下跌20.1%，同期标普500指数上涨2.7%，医疗板块下跌3.3% [13] - 过去三个月股价下跌22.4%，同期标普500指数上涨13.2%，医疗板块下跌1.8% [13] 行业分析 - 国际业务可对冲本土经济风险，但面临汇率波动、地缘政治等复杂因素 [3] - 华尔街高度关注全球化企业的海外收入趋势以修正盈利预测 [10] - 医疗板块近期表现弱于大盘，三个月累计跌幅1.8% [13] 公司评级 - 当前Zacks评级为3（持有），预示短期表现与市场持平 [12] - 盈利预测修正与股价走势呈正相关，但未披露具体调整幅度 [11]